SEC Filings
State Street Holds 5.1% Of CareDx Without Seeking To Influence Control
The passive holding totaled 2,623,064 shares, alongside CareDx's higher 2026 revenue outlook.
SEC Filings
The passive holding totaled 2,623,064 shares, alongside CareDx's higher 2026 revenue outlook.
SEC Filings
The company raised its annual revenue floor to $25 million, while unfilled orders fell 24% during the quarter.
SEC Filings
The reported position covered 1,810,255 shares, with voting authority shared over most of the holding.
SEC Filings
Initial ISEMBYLD shipments brought in $0.6 million, with first patient infusions in October and overseas regulatory reviews underway.
SEC Filings
Centrus's quarterly sales fell 26%, while management said contingent enrichment sales commitments reached $5.4 billion.
SEC Filings
The September 30 holding comes alongside renewed ETF buying and a Morgan Stanley downgrade ahead of Thursday's earnings.
SEC Filings
The passive holding comes as ADHD-drug sales grow, generic competition cuts pain revenue and quarterly profit falls.
SEC Filings
The September 30 position covered 6,739,385 shares, held in ordinary business activity rather than for a control effort.
SEC Filings
Corvus expects its cash to last into the second quarter of 2028, with a lymphoma-study assessment expected in early 2027.
SEC Filings
The holding covered nearly 5 million shares as of September 30, while CRISPR's experimental triglyceride treatment remains at an early stage.
SEC Filings
The holding covered 2,930,133 shares as of September 30, 2026, and was below the 5% threshold.
SEC Filings
The passive position was dated September 30; Cullinan reported preliminary velinotamig results Sunday.